MHMohamed El Hag

Mohamed El Hag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed El Hag has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Banff liver allograft pathology group: late rejection activity is insufficiently represented in the current diagnostic framework—rationale and goals for reveision

    by Christopher Bellamy, Claudia Mescoli, Khashayar Asadi, Oyedele A. Adeyi, Rachel M. Brown, Lindsey Clarke, Zeynep Demir, Sadhna Dhingra, Michail Doukas, Mohamad El Hag, et al.

  • Top Cited Papers
    Open Access

    Bridging therapy with histotripsy prior to liver transplantation for hepatocellular carcinoma: a first case report

    by Melis Uysal, Chase J Wehrle, Christopher Coppa, Suneel Kamath, Smitha Krishnamurthi, Charles Martin, Mohamed El Hag, Mazhar Khalil, Masato Fujiki, Andrea Schlegel, et al.

    Background: Histotripsy is a novel, non-invasive, non-ionizing, and non-thermal ablation technique that disrupts tumors using acoustic cavitation. We report the first use of Histotripsy as bridging therapy prior to liver transplant for hepatocellular carcinoma (HCC) treated with histotripsy. Case presentation: A 59-year-old woman presented with Metabolic-Associated Steatotic Liver Disease (MASLD) cirrhosis (labMELD = 14), hepatic encephalopathy, and a single 2 cm OPTN V lesion in the left lateral segment consistent with HCC. The patient underwent histotripsy treatment of the lesion as bridging therapy before receiving liver transplantation. Histopathology analysis of the explanted liver showed total necrosis of the treated area, with no residual viable tissue tumor. Conclusion: This case demonstrates the potential utility of histotripsy as an effective bridging therapy for patients with combined cirrhosis and hepatocellular carcinoma (HCC) awaiting liver transplantation, with complete tumor necrosis on explant pathology demonstrating its therapeutic efficacy.


  • Is PAS Stain Necessary to Exclude Whipple Disease in Duodenal Biopsies?

    by Ahmed Bakhshwin, Lauren Ashley Duckworth, Paula Toro Castano, Mohamed El Hag, Thomas Plesec

    Objective. Whipple disease, caused by Tropheryma whipplei , is a rare infectious condition primarily presenting with malabsorptive diarrhea. Small bowel biopsies typically reveal foamy macrophages containing periodic acid–Schiff-positive/diastase (PAS/D) resistant T. whipplei bacilli, and PAS(D) staining is occasionally requested by clinicians in duodenal biopsies, which are often histologically unremarkable. The yield of PAS(D) staining in such biopsies has never been reported to our knowledge. Methods. The anatomic pathology database was searched for all specimens of duodenal biopsies stained with PAS(D) from 1993 to 2021. Specimens were categorized by the following histomorphologic features: unremarkable, nonspecific changes, or expansion of the lamina propria by aggregates of foamy histiocytes. Follow-up information was collected, including microbiologic confirmatory testing. Results. There was a total of 193 specimens of duodenal biopsies stained with PAS(D). Biopsies lacking foamy histiocytes on H&E ( n = 158) were never PAS-positive. Thirteen biopsies contained PAS-positive histiocytes; 9 out of the 13 PAS-positive specimens were subsequently confirmed to be T. whipplei . Of the 193 specimens, 124 specimens had a clinical request for PAS(D) staining. Only 3 of the 124 (2.4%) specimens showed foamy histiocytes containing PAS-positive granules, all of which were confirmed positive for T. whipplei . Conclusion. PAS(D) staining is unnecessary to exclude Whipple disease in duodenal biopsies without foamy macrophage aggregates, regardless of clinical suspicion. Clinical suspicion-driven biopsies often yield negative results for Whipple disease.

  • Open Access

    Immunotactoid hepatopathy: A novel entity with histologically proven recurrence post liver transplantation

    by Ahmed Bakhshwin, Leal Herlitz, Shaomin Hu, Shahzad Raza, Dane C. Olevian, Ali Mehdi, Kenneth Friedman, Bijan Eghtesad, Koji Hashimoto, Jamak Modaresi Esfeh, et al.

  • Open Access

    Morphologic and immunophenotypic evaluation of liver allograft biopsies with contemporaneous serum DSA measurements

    by Mohamed I. El Hag, Hugo Kaneku, Dana Jorgensen, Adriana Zeevi, Heather L. Stevenson, Nour Yadak, Mohamed Hassan, Xiaotang Du, Anthony J. Demetris

    Background: Acute antibody mediated rejection is increasingly identified in liver allografts as a unique form of alloimmune injury associated with donor specific antibodies (DSA). This manifests pathologically as microvascular injury and C4d uptake. Despite the liver allograft's relative resistance to alloimmune injury, liver allografts are not impervious to cellular and antibody‐mediated rejection.Methods: In this blinded control study, we evaluated CD163 immunohistochemistry and applied the Banff 2016 criteria for diagnosis of acute AMR on a group of indication allograft liver biopsies from DSA positive patients and compared them to indication biopsies from DSA negative controls.Results: Most DSA positive patients were females (75%, p = .027), and underwent transplantation for HCV infection. Significant histopathological predictors of serum DSA positivity were Banff H‐score (p = .01), moderate to severe cholestasis (p = .03), and CD163 score > 2 (p = .029). Other morphologic features that showed a trend with DSA positivity include Banff portal C4d‐score (p = .06), bile ductular reaction (p = .07), and central perivenulitis (p = .07). The odds of DSA sMFI ≥5000 was 12.5 times higher in those with a C4d score >1 than those with a C4d score ≤ 1 (p = .04). Incidence of definite for aAMR in the DSA positive cohort was 25% (n = 5), and 0% in the DSA negative cohort. A group of 5 DSA positive cases were not classifiable by the current scheme.Conclusion: Sinusoidal CD163, Banff H‐score, and diffuse C4d are predictors of serum DSA, and facilitate recognition of histopathological features associated with serum DSA and tissue–antibody interaction.


  • Inhibin-Positive “Cholangioblastic” Variant of Intrahepatic Cholangiocarcinoma: Report of 3 New Patients With Review of the Literature

    by Ahmed Bakhshwin, Keith K. Lai, Alwalid Ammoun, Kenneth Friedman, Mohamed El Hag

    Cholangiocarcinoma is the second most common primary liver malignant neoplasm. It usually affects older individuals in their seventh decade of life with no gender predilection. Recently, a distinct subtype of cholangiocarcinoma has emerged with 2 proposed names: “cholangioblastic” and “solid tubulocystic.” This variant predominantly occurs in younger women who lack the common risk factors for patients diagnosed with cholangiocarcinomas, such as older age and chronic liver disease or cirrhosis. We describe 3 new patients with a cholangioblastic variant of intrahepatic cholangiocarcinoma. At the time of diagnosis, the patients were aged 19-, 46-, and 28-year-old; 2 females and 1 male (the 46-year-old). None of our patients had a history of chronic liver disease or known predisposing factors for liver tumors. Tumor size ranged from 2.3 to 23 cm in greatest dimension. Histological examination of these tumors demonstrated reproducible morphology characterized by trabecular, nested, and multicystic patterns with micro and macro follicles filled with eosinophilic material. The immunohistochemical profile showed that the tumor cells were positive for keratin 7, inhibin, synaptophysin, and albumin in situ hybridization, while negative for HepPar1, arginase, and INSM1. All tumors lacked conventional intrahepatic cholangiocarcinoma/adenocarcinoma morphology. We also review the literature and emphasize that neuroendocrine tumors should be recognized as a major diagnostic pitfall of this variant.


  • Open Access

    Esophageal Carcinoma Cuniculatum Associated with Non-Necrotizing Granulomatous Inflammation and Lymphadenopathy: Clinicopathologic Features and Diagnostic Challenges

    by Toni M. Dick, Mohamed El Hag, J. Shawn Mallery, Khalid Amin

    BACKGROUND:Esophageal carcinoma cuniculatum (CC) is an exceptionally rare, well-differentiated squamous cell carcinoma (SCC) with initial microscopic evaluation often yielding inconclusive diagnoses due to its characteristically bland histomorphologi...


  • Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study

    by Mohamed I. El Hag, Amani M. Hag, Jennifer P. Ha, Claire W. Michael

    Background: GATA-3 is a potential marker for detection of metastatic breast carcinoma, reportedly more sensitive than mammaglobin (MAM) and GCDFP-15. We aim to compare the sensitivity of GATA-3, MAM and GCDFP-15 in determining the breast origin of malignant effusions. Methods: Cell blocks from 27 cases of serous effusions positive for metastatic breast cancer were retrieved. Immunohistochemistry for GATA-3, MAM, gross cystic disease fluid protein 15 (GCDFP-15), estrogen receptor (ER) and progesterone receptor (PR) was performed on cell-block micro-array. Statistical analysis using two ways Chi square, one-way ANOVA and multiple regression was performed. Results: The detection rate of breast cancer in serous fluid was significantly higher with GATA-3 (88.8 %, X2=15.9, p=0.00034) than with MAM (51.8 %) and GCDFP-15 (37.0 %). All ER positive cases (19) were GATA-3 positive. Conversely, all GATA-3 negative cases (3) were ER negative. The intensity of stain and percentage of positive cells were significantly higher with GATA-3 (p<0.0001) than with MAM and GCDFP-15. The intensity and percentage of positive cells score of GATA-3 were statistically associated with ER stain intensity and percentage of positive cell scores. Conclusions: GATA3 is a sensitive marker, superior to MAM and GCDFP-15 in determining the breast origin of metastatic adenocarcinoma. It is also strongly associated with ER expression.


  • Can Medullary Thyroid Carcinoma Arise in Thyroglossal Duct Cysts? A Search for Parafollicular C-cells in 41 Resected Cases

    by Tracy Stein, Paari Murugan, Faqian Li, Mohamed I. El Hag

    Thyroglossal duct cysts (TGDCs) are present in ~7% of adults and develop from the midline migratory tract between the foramen cecum and anatomic location of the thyroid. Thyroid tissue can be identified in 2/3 of TGDCs, and up to 1% develop associated malignancy, 90% of which are papillary thyroid carcinoma. Cases of follicular and anaplastic carcinoma have been documented, but there are no reports of medullary thyroid carcinoma arising in a TGDC. This is presumably due to the distinct embryologic origin of parafollicular C-cells, from which medullary carcinoma arises. The goal of this study is to determine whether parafollicular C-cells are present in TGDCs. H&E sections from 41 TGDC cases were examined for thyroid tissue, thyroglossal duct remnants, ultimobranchial remnants, and parafollicular C-cells. Immunohistochemistry was performed for TTF-1 and calcitonin. Eighty three percent (34/41) of cases contained thyroid tissue on H&E and by TTF-1. No cases (0/41) had ultimobranchial remnants or parafollicular C-cells on H&E or with calcitonin. One case of papillary carcinoma in a TGDC was identified. These cases illustrate that although TGDCs often contain thyroid tissue, parafollicular C-cells are absent. Therefore, unlike other thyroid neoplasms, there is no evidence to support the possibility of medullary carcinoma arising in a TGDC.


  • Utility of TTF‐1 and Napsin‐A in the work‐up of malignant effusions

    by Mohamed El Hag, Lindsay Schmidt, Michael Roh, Claire W. Michael

    Background: Similar to TTF‐1, Napsin‐A is recently used increasingly to differentiate between pulmonary adenocarcinoma (P‐ADC) and extra‐pulmonary adenocarcinoma (EP‐ADC). The aim of this study was to compare the performance of TTF‐1 and Napsin‐A in determining the primary origin of adenocarcinoma in malignant serous effusion.Methods: Following IRB approval, cellblocks from 139 cases of malignant serous effusions of histologically or clinically determined origin including: 26 P‐ADC, 108 EP‐ADC, 2 pulmonary squamous cell carcinoma (P‐SQC), and 3 pulmonary small cell carcinoma (P‐SCC) were retrieved. Each case was stained with Napsin‐A and TTF‐1 and evaluated for positivity and intensity of staining.Results: Napsin‐A and TTF‐1 stained positive in 17/26 (65%) and 14/26 (54%) of P‐ADC and in 2/108 (1.8%) and 0/108 (0%) of EP‐ADC with a PPV of 89 and 100%, respectively. In combination, they positively stained 18/26 (70%) of P‐ADC with a PPV of 90%. Out of 9 poorly differentiated P‐ADC, 7 (78%) stained positive for Napsin‐A, while 4 (45%) were reactive for TTF‐1. Both Napsin‐A and TTF‐1 were negative in P‐SQC, while P‐SCC reacted positively for TTF‐1 in 2/3 (66%) of cases and none for Napsin‐A.Conclusion: Napsin‐A and TTF‐1 are both useful markers in distinguishing P‐ADC from EP‐ADC. However, Napsin‐A performed better in poorly differentiated P‐ADC and its mimickers. The nuclear staining of TTF‐1 is crispier and much easier to interpret than Napsin‐A cytoplasmic stain. An antibody panel including TTF‐1 and Napsin‐A or a dual stain will be very helpful in determining the origin of metastatic adenocarcinoma in serous effusion. Diagn. Cytopathol. 2016;44:299–304.